Research Article
Vascular Endothelial Growth Factor Is Associated with the Morphologic and Functional Parameters in Patients with Hypertrophic Cardiomyopathy
Table 1
Patient demographic and clinical characteristics.
| | HCM () |
| Age (years) | 58.4 ± 13.2 | Female gender, (%) | 6 (28) | Atrial fibrillation, (%) | 7 (33) | Creatine level (mol⋅L−1) | 92 ± 14 | Diabetes mellitus, (%) | 9 (43) | Hyperlipidemia, (%) | 14 (66) | Smoking, (%) | 7 (33) | NYHA functional class, (%): | | I | 8 (38) | II | 10 (47) | III-IV | 3 (14) | Therapy | | Medication, (%) | | Calcium channel blocker | 10 (47) | -blockers | 12 (57) | Diuretics | 8 (38) | ACE inhibitors/sartans | 9 (42) | Implantable devices, (%) | | DDD pacing | 5 (24) | ICD/BiV | 1 (4) |
|
|
NYHA, New York Heart Association; ACE, angiotensin converting enzyme; DDD, dual chamber pacing; ICD, implantable cardioverter/defibrillator; and BiV, biventricular pacing.
|